Last week, we had the opportunity to listen to Psyched Wellness CEO Jeff Stevens (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) speak at Canaccord Genuity’s New Paradigms & Treatment Approaches in Mental Health Conference.
Although we had a firm understanding of Psyched Wellness’ business prior to the presentation, we left feeling increasingly excited about the direction the business is going. After listing to several presentations during the conference, we believed that Psyched stood out as a differentiated play on the psychedelic therapy and functional mushroom market.
Discovering the Medical Properties that are Associated with Muscimol
Psyched is a life sciences company that is focused on the production and distribution of artisanal functional and psychedelic mushrooms. A few weeks ago, the company issued an update on a previously announced study that would determine the therapeutic values that are associated with muscimol for antioxidant and anti-inflammatory purposes through a nerve derived immunity and neuroprotective modulation models.
The study is focused on determining the effectiveness of Amanita Muscaria Extract-1 (AME-1) as well as the active compound muscimol from the Amanita Muscaria mushroom for potential dual antioxidant and anti-inflammatory properties. Psyched has already completed an initial set of preclinical tests that examine potential allergenicity and the results show that AME-1 does not have any allergenic properties in an invitro cell-based mast cell model. The initial findings support that AME-1 is not allergenic and as such will not show signs of hypersensitivity when used in a supplement form.
Going forward, Psyched plans to conduct additional studies to gain evidence that will further support the initial findings from the set of preclinical tests. Currently, the company is conducting antioxidant and anti-inflammatory studies and we will monitor how the data supports this aspect of the business.
AME-1 was developed as part of a process of trial and error studies to create the ideal extract for future Psyched products. The company believes AME-1 will be the base for future Amanita Muscaria product lines on both the health and wellness and the pharmaceutical side of the business. As part of its ongoing research and development, Psyched continues to work to identify novel uses for AME-1 and plans to build a patent portfolio for new pharmacologically optimized psychedelic medicines that is centered around AME-1.
An Opportunity with Visible Growth Catalysts
One of the reasons we are excited about Psyched is related to the path that AME-1 can take to market that is shorter and requires less regulatory hurdles. We are favorable on the focus on creating a portfolio of strategic intellectual property (IP) and consider this to be a key pillar of the story. Going forward, Psyched plans to continue to identify novel uses for AME-1 and will look to build a patent portfolio for new pharmacologically optimized psychedelic medicines.
Another reason for our positive outlook on Psyched is related to the strength of the leadership team. The research was led by Professor David Nutt who is the head of the company’s scientific committee and we are favorable on the experience that he brings to the organization. Nutt is a psychiatrist and is the Chair of the Scientific Advisory Board for COMPASS Pathways Inc. (CMPS) and we believe he adds invaluable expertise to the team.
We consider Psyched to an attractive play on the psychedelic therapy and functional mushroom market. At current levels, we believe the business has a compelling valuation and an attractive risk-reward profile. We believe Psyched is reaching an inflection point and has significant potential catalysts for growth. On a comparative basis, the company is trading at a discount to its peers and this is an opportunity that our readers need to be aware of.
If you are interested in learning more about Psyched Wellness, please send an email to firstname.lastname@example.org with the subject “Psyched Wellness” to be added to our distribution list.